Credit: Sentynl Therapeutics. Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease. Approval of copper ...

Add Yahoo as a preferred source to see more of our stories on Google. Zycubo is administered subcutaneously to restore copper balance and maintain appropriate copper levels in affected patients.

The FDA on Jan. 12 approved Zycubo injection as the first treatment for children with Menkes disease. Menkes disease is a rare neurodegenerative disorder that hinders a child’s ability to absorb ...

(RTTNews) - Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprian Therapeutics, Inc., on Tuesday said the U.S. Food and Drug Administration has approved ZYCUBO for the treatment of ...

Six-month priority review granted for CUTX-101 copper histidinate with PDUFA target action date set for June 30, 2025 CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease, ...

The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency announced Monday. The treatment is a subcutaneous injectable formulation of ...

rolling submission of New Drug Application to FDA is ongoing and expected to be completed in 2024 Sentynl now assumes full responsibility for the development and commercialization of CUTX-101. In 2021 ...

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a 3-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital to fund ...

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients. Approval of Zycubo was granted to Sentynl ...

Approval of copper histidinate (Zycubo) provides a new treatment for Menkes disease by bypassing impaired gastrointestinal copper absorption. The Food and Drug Administration (FDA) has approved Zycubo ...